{
    "clinical_study": {
        "@rank": "87408", 
        "arm_group": [
            {
                "arm_group_label": "Short term warfarin group", 
                "arm_group_type": "Experimental", 
                "description": "taking warfarin for only 2 weeks after catheter ablation of atrial fibrillation"
            }, 
            {
                "arm_group_label": "Conventional therapy arm", 
                "arm_group_type": "Active Comparator", 
                "description": "conventional warfarin therapy of 3 weeks before and 8 weeks after catheter ablation of AF"
            }
        ], 
        "brief_summary": {
            "textblock": "We hypothesized that in patients with low CHADS-VASc score (2 or < 2), there is no\n      difference in thromboembolic or bleeding events between patients with short term warfarin\n      therapy (2 weeks after catheter ablation) and conventional therapy (3 weeks before and 8\n      weeks after procedure)."
        }, 
        "brief_title": "Short Term Warfarin Therapy for Radiofrequency Catheter Ablation of Atrial Fibrillation", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with paroxysmal atrial fibrillation who underwent radiofrequency catheter\n             ablation\n\n          -  Patients with CHADS-VASc score 2 or less than 2\n\n        Exclusion Criteria:\n\n          -  Patients who do not consent to the study\n\n          -  Permanent or persistent atrial fibrillation\n\n          -  Patients who have underwent prior catheter ablation for atrial fibrillation\n\n          -  CHADS-VASc score more than 2\n\n          -  History of stroke\n\n          -  LVEF <40%\n\n          -  Significant liver or kidney dysfunction\n\n          -  History of major bleeding during warfarin therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "520", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991951", 
            "org_study_id": "KUMCEP01"
        }, 
        "intervention": {
            "arm_group_label": [
                "Short term warfarin group", 
                "Conventional therapy arm"
            ], 
            "intervention_name": "warfarin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Warfarin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 21, 2013", 
        "location": {
            "contact": {
                "email": "jshim@kumc.or.kr", 
                "last_name": "Jaemin Shim, MD", 
                "phone": "82-10-6776-1195"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "136-705"
                }, 
                "name": "Korea University Anam Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective Randomized Study of Incidence of Thromboembolic and Bleeding Events According to the Period of Warfarin Use Before and After Catheter Ablation of Paroxysmal Atrial Fibrillation in Low Risk Patients", 
        "overall_contact": {
            "email": "jshim@kumc.or.kr", 
            "last_name": "Jaemin Shim, MD", 
            "phone": "82-10-6776-1195"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of thromboembolic and bleeding events during 2 months", 
            "safety_issue": "Yes", 
            "time_frame": "2 months after the procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991951"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Korea University Anam Hospital", 
            "investigator_full_name": "Young-Hoon Kim", 
            "investigator_title": "Professor of medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Korea University Anam Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Korea University Anam Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}